Marco Cerrano

Germline DDX41 mutations define a significant entity within adult MDS/AML patients

Marie Sébert, Marie Passet, Anna Raimbault et al. · Blood · 2019 · 202 citations

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso et al. · Blood Advances · 2019 · 89 citations · Full text

Mixed-phenotype Acute Leukemia, Pathology, Cell Replacement Therapy +16

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Sabina Chiaretti, Monica Messina, Irene Della Starza et al. · Haematologica · 2020 · 78 citations · Full text

Poor Outcome, Mixed-phenotype Acute Leukemia, Immunology +16

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

Carmen Fava, Giovanna Rege‐Cambrin, Irene Dogliotti et al. · Haematologica · 2019 · 75 citations · Full text

Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study

Anna Candoni, Davide Lazzarotto, Felicetto Ferrara et al. · American Journal of Hematology · 2020 · 67 citations · Full text

Cell Therapy, Mixed-phenotype Acute Leukemia, Cell Replacement Therapy +21